Abstract
Warfarin is prescribed to millions of Americans for the management of thromboembolism and is a common cause of adverse events. Optimizing warfarin therapy has been the focus of national quality improvement initiatives. Anticoagulation clinics have been demonstrated to result in better outcomes than usual care. Nevertheless, Highmark Medicare Services recently issued a provider bulletin on anticoagulation clinic visit reimbursement that we believe will adversely affect the care for patients on anticoagulation. In this commentary, we review the potential unintended consequences of this proposal and offer alternatives that we believe will increase the efficiency and quality of anticoagulation management.
Original language | English (US) |
---|---|
Pages (from-to) | 733-736 |
Number of pages | 4 |
Journal | Annals of Pharmacotherapy |
Volume | 44 |
Issue number | 4 |
DOIs |
|
State | Published - Apr 1 2010 |
Keywords
- Anticoagulation
- Anticoagulation clinic
- Center for Medicare
- Health-care economics
- Medicaid Services
- Warfarin
ASJC Scopus subject areas
- Pharmacology (medical)